Table 2.
Distribution of osteoporosis treatments in cohort 1a.
| Among all patients |
Among treated patients |
|
|---|---|---|
| (N = 18,813) | (N = 3181) | |
| No treatment | 15,632 (83.1) | – |
| Bisphosphonates | 2856 (15.2) | 2856 (89.8) |
| Alendronate | 2017 (10.7) | 2017 (63.4) |
| Ibandronateb | 105 (0.6) | 105 (3.3) |
| Risedronate | 729 (3.9) | 729 (22.9) |
| Zoledronateb | 5 (0.03) | 5 (0.2) |
| Non-bisphosphonates | 325 (1.7) | 325 (10.2) |
| Strontium | 75 (0.4) | 75 (2.4) |
| Calcitonin | 70 (0.4) | 70 (2.2) |
| Raloxifene | 180 (1.0) | 180 (5.7) |
| Teriparatide | 0 (0.0) | 0 (0.0) |
| Parathyroid hormone | 0 (0.0) | 0 (0.0) |
a
Values are presented as N (%). Treatment categories are mutually exclusive.
b
Includes all injectable and infusion forms.